Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer.

González-Martín A, Pothuri B, Vergote I, Graybill W, Lorusso D, McCormick CC, Freyer G, Backes F, Heitz F, Redondo A, Moore RG, Vulsteke C, O'Cearbhaill RE, Malinowska IA, Shtessel L, Compton N, Mirza MR, Monk BJ

Open source

DOI: 10.1016/j.ejca.2023.04.024
Published: 2023 Aug
Container: European journal of cancer (Oxford, England : 1990)
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ejca.2023.04.024,
  title = {Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer.},
  author = {González-Martín A and Pothuri B and Vergote I and Graybill W and Lorusso D and McCormick CC and Freyer G and Backes F and Heitz F and Redondo A and Moore RG and Vulsteke C and O'Cearbhaill RE and Malinowska IA and Shtessel L and Compton N and Mirza MR and Monk BJ},
  year = {2023},
  journal = {European journal of cancer (Oxford, England : 1990)},
  doi = {10.1016/j.ejca.2023.04.024},
  url = {https://doi.org/10.1016/j.ejca.2023.04.024}
}

RIS

TY  - JOUR
TI  - Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer.
AU  - González-Martín A
AU  - Pothuri B
AU  - Vergote I
AU  - Graybill W
AU  - Lorusso D
AU  - McCormick CC
AU  - Freyer G
AU  - Backes F
AU  - Heitz F
AU  - Redondo A
AU  - Moore RG
AU  - Vulsteke C
AU  - O'Cearbhaill RE
AU  - Malinowska IA
AU  - Shtessel L
AU  - Compton N
AU  - Mirza MR
AU  - Monk BJ
PY  - 2023
JO  - European journal of cancer (Oxford, England : 1990)
DO  - 10.1016/j.ejca.2023.04.024
UR  - https://doi.org/10.1016/j.ejca.2023.04.024
ER  -

APA

A, G., B, P., I, V., W, G., D, L., CC, M., G, F., F, B., F, H., A, R., RG, M., C, V., RE, O., IA, M., L, S., N, C., MR, M., & BJ, M. (2023). Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer.. European journal of cancer (Oxford, England : 1990). https://doi.org/10.1016/j.ejca.2023.04.024

Source records

pubmed · retrieved 2026-09-26T04:09:06.621Z